Research Summary

I am a physician scientist who works in translational cancer research and medical oncology. My clinical practice is in the Cancer Immunotherapy Clinic, where I work with patients with solid organ cancers who are being treated on early phase immunotherapy trials. I also attend on the Oncology Consult inpatient service. My research interests are in studying the mechanisms of response and resistance to immunotherapy, with a focus on gastrointestinal cancers.


  • Loyola University, BS, 2006, Biology, Chemistry
  • Johns Hopkins University, MD, PhD, 2015, Medicine, Immunology
  • University of California San Francisco, Residency, 2017, Internal Medicine
  • University of California San Francisco, Fellowship, Hematology/Oncology

Honors & Awards

  • 2022
    ImFLAME Young Investigator Award
  • 2022 
    HDFCCC K12 Physician Scholar Program in Clinical Oncology Career Development Award
  • 2022
    UCSF Liver Center Liver Center Pilot/Feasibility Grant Awardee
  • 2022
    HDFCCC Cancer Immunology and Immunotherapy Pilot Grant Awardee
  • 2021
    UCSF Chancellor Award for Advancement of Women
  • 2021
    The Cholangiocarcinoma Foundation Research Fellowship Award
  • 2020
    UCSF Exceptional Physician Award Honorable Mention
  • 2020
    ANCO (Association of Northern California Oncologists) Travel Award
  • 2020
    ASCO Conquer Cancer Foundation Young Investigator Award
  • 2020
    Society for Translational Oncology Fellows’ Forum, selected participant
  • 2019
    Scholar-in-Training Award, AACR Annual Meeting 2019
  • 2018-2019
    UCSF Fellowship Leadership Cohort 
  • 2018, 2019
    Immunology T32 training grant recipient
  • 2018
    UCSF Academy of Medical Educators Innovations Funding for Education Grant Awardee 
  • 2018
    AACR Molecular Biology in Clinical Oncology course participant 
  • 2017
    UCSF Excellence and Innovation Award in Graduate Medical Education for developing WILD (Women in Leadership Development) annual symposium

Selected Publications

  1. Keenan BP, McCarthy EE, Ilano A, Yang H, Zhang L, Allaire K, Fan Z, Li T, Lee DS, Sun Y, Cheung A, Luong D, Chang H, Chen B, Marquez J, Sheldon B, Kelley RK, Ye CJ, Fong L. Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T�cell paralysis. Cell Rep. 2022 09 20; 40(12):111384.  View on PubMed
  2. Andrea Grace Bocobo, Renee Wang, Spencer Behr, Julia C. Carnevale, Pelin Cinar, Eric Andrew Collisson, Lawrence Fong, Bridget P Keenan, Wesley Allen Kidder, Andrew H. Ko, Kanti Pallav Kolli, Megan Kennedy, Angela Laffan, Sorbarikor Piawah, Marin Pollak, Gabriel Schwartz, Julia Whitman, Li Zhang, Katherine Van Loon, Chloe Evelyn Atreya. Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 2022 Jun 1; 40(16_suppl):3565-3565.  View on PubMed
  3. Robin Kate Kelley, Paige M. Bracci, Bridget Keenan, Spencer Behr, Faaiz Ibrahim, Marin Pollak, John Gordan, Andrew H. Ko, Katherine Van Loon, Chloe Evelyn Atreya, Pelin Cinar, Alan P. Venook, Lawrence Fong. Pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Final outcomes of a phase 2 trial. Journal of Clinical Oncology. 2022 Feb 1; 40(4_suppl):444-444.  View on PubMed
  4. Bridget Keenan, Elizabeth McCarthy, Arielle Ilano, Hai Yang, Li Zhang, Kathryn Allaire, Zenghua Fan, Tony Li, David Lee, Yang Sun, Alexander Cheung, Hewitt Chang, Brenna Sheldon, Robin Kelley, Chun Jimmie Ye, Lawrence Fong. 676 Altered circulating myeloid states associated with anti-PD-1 resistance induce T cell paralysis in human biliary cancer. Journal for ImmunoTherapy of Cancer. 2021 Nov 10; 9(Suppl 2):a704-a704.  View on PubMed
  5. Keenan BP, VAN Loon K, Khilnani AD, Fidelman N, Behr SC, Atreya CE, Oh DY. Molecular and Radiological Features of Microsatellite Stable Colorectal Cancer Cases With Dramatic Responses to Immunotherapy. Anticancer Res. 2021 Jun; 41(6):2985-2992.  View on PubMed
  6. Keenan B, Jagsi R, Van Loon K. Pragmatic Solutions to Counteract the Regressive Effects of the COVID-19 Pandemic for Women in Academic Oncology. JAMA Oncol. 2021 06 01; 7(6):825-826.  View on PubMed
  7. Keenan BP, Kelley RKK. Key challenges for drugs in clinical development for cholangiocarcinoma. Expert Opin Investig Drugs. 2021 Apr; 30(4):285-290.  View on PubMed
  8. Keenan BP, Fong L. Conditional Cancer Immunotherapy as a Safer Way to Step on the Gas. Cancer Discov. 2021 01; 11(1):20-22.  View on PubMed
  9. Santhosh L, Harleman E, Venado A, Farrand E, E Gilbreth M, Keenan BP, Thompson VV, Shah RJ. Strategies for forming effective women's groups. Clin Teach. 2021 Apr; 18(2):126-130.  View on PubMed
  10. Bridget P. Keenan, Elizabeth E. McCarthy, Arielle Ilano, David S. Lee, Yang Sun, Brenna Sheldon, Alexander Cheung, Chun Jimmie Ye, Robin Kate Kelley, Lawrence Fong. Abstract 5512: Identification of circulating myeloid cells induced in advanced biliary cancer patients responding to anti-PD1 through combined single cell RNA sequencing and protein expression analysis. Cancer Research. 2020 Aug 15; 80(16_Supplement):5512-5512.  View on PubMed
  11. Santhosh L, Keenan BP, Jain S. The "Third Shift": A Path Forward to Recognizing and Funding Gender Equity Efforts. J Womens Health (Larchmt). 2020 11; 29(11):1359-1360.  View on PubMed
  12. Chu NJ, Anders RA, Fertig EJ, Cao M, Hopkins AC, Keenan BP, Popovic A, Armstrong TD, Jaffee EM, Zimmerman JW. Inhibition of miR-21 Regulates Mutant KRAS Effector Pathways and Intercepts Pancreatic Ductal Adenocarcinoma Development. Cancer Prev Res (Phila). 2020 07; 13(7):569-582.  View on PubMed
  13. Keenan BP, Fong L, Kelley RK. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. J Immunother Cancer. 2019 10 18; 7(1):267.  View on PubMed
  14. Lowery MA, Goff LW, Keenan BP, Jordan E, Wang R, Bocobo AG, Chou JF, O'Reilly EM, Harding JJ, Kemeny N, Capanu M, Griffin AC, McGuire J, Venook AP, Abou-Alfa GK, Kelley RK. Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes. Cancer. 2019 Dec 15; 125(24):4426-4434.  View on PubMed
  15. Bridget P. Keenan, Whitney Tamaki, Eric Liu, Brandon Chen, Alexander Cheung, John D. Gordan, Brenna Sheldon, Li Zhang, Robin K. Kelley, Lawrence Fong. Abstract 4063: Single cell immune profiling of patients with advanced biliary cancers treated with combination checkpoint inhibition and GM-CSF reveals diverse T cell and myeloid cell mechanisms of action. Cancer Research. 2019 Jul 1; 79(13_Supplement):4063-4063.  View on PubMed
  16. Kambhampati S, Bauer KE, Bracci PM, Keenan BP, Behr SC, Gordan JD, Kelley RK. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series. Cancer. 2019 09 15; 125(18):3234-3241.  View on PubMed
  17. Keenan B, Santhosh L, Thompson V, Harleman E. The Complex Problem of Women Trainees in Academic Medicine. J Hosp Med. 2019 03; 14(3):186-188.  View on PubMed
  18. Bridget Keenan, Madeline J Griffith, Kelly Bauer, Paige M. Bracci, Spencer Behr, Sarah E Umetsu, John Dozier Gordan, Zoe Ngo, Syma Iqbal, Diana L. Hanna, Alan P. Venook, Anthony B. El-Khoueiry, Lawrence Fong, Robin Kate Kelley. Phase II multicenter pilot study of safety, efficacy, and immune cell profiling in advanced hepatocellular carcinoma (HCC) on combination of sorafenib (SOR) plus nivolumab (NIVO). Journal of Clinical Oncology. 2019 Feb 1; 37(4_suppl):tps464-tps464.  View on PubMed
  19. Robin Kate Kelley, Emily Mitchell, Spencer Behr, Jimmy Hwang, Bridget Keenan, Sarah E Umetsu, John Dozier Gordan, Andrew H. Ko, Pelin Cinar, Chloe Evelyn Atreya, Katherine Van Loon, Thomas Weber, Zoe Ngo, Zoe E. Quandt, Chienying Liu, Alan P. Venook, Lawrence Fong. Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker analyses. Journal of Clinical Oncology. 2018 May 20; 36(15_suppl):4087-4087.  View on PubMed
  20. Robin Kate Kelley, Emily Mitchell, Spencer Behr, Jimmy Hwang, Bridget Keenan, Alexander Cheung, John Dozier Gordan, Andrew H. Ko, Pelin Cinar, Chloe Evelyn Atreya, Katherine Van Loon, Thomas Weber, Zoe Ngo, Zoe E. Quandt, Chienying Liu, Alan P. Venook, Lawrence Fong. Phase II trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC). Journal of Clinical Oncology. 2018 Feb 1; 36(4_suppl):386-386.  View on PubMed

Go to UCSF Profiles, powered by CTSI